Business
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Palazestrant’s mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen receptorOP-3136, in combination with palazestrant, exhibits synergistic anti-tumor activity in ER+/HER2- breast cancer models driven by suppression of cell-cycle and estrogen receptor-driven oncogenic signalingPalazestrant is currently being evaluated in two Phase 3 clinical trials; OP-3136 is enrolling patients in the ongoing Phase 1 study SAN FRANCISCO, April
About this update from Olema Pharmaceuticals, Inc.
[{"type":"image","alt":"Olema Oncology","displaySize":"","headline":null,"caption":"Olema Oncology","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/b0eb35a98097b94ad61fdfb6ead09122"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8WMDEniZEx5HC3l8.Api5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/b0eb35a98097b94ad61fdfb6ead09122","width":300,"height":86}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Palazestrant’s mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen receptor","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"OP-3136, in combination with palazestrant, exhibits synergistic anti-tumor activity in ER+/HER2- breast cancer models driven by suppression of cell-cycle and estrogen receptor-driven oncogenic signaling","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"Palazestrant is currently being evaluated in two Phase 3 clinical trials; OP-3136 is enrolling patients in the ongoing Phase 1 study","length":132,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":478,"olType":false},{"type":"text","content":"SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced new preclinical data for palazestrant, a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), alone and in combination with OP-3136, a novel small molecule that potently and selectively inhibits acetyltransferase 6 (KAT6) inhibitor. The data will be presented in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22 in San Diego, California.","length":745,"tagName":"p"},{"type":"text","content":"“We are very excited to share, for the first time ever, data that confirm the mechanism by which palazestrant completely blocks estrogen receptor transcription and signaling by recruiting the corepressor protein NCoR1,” said David C. Myles, Ph.D., Chief Scientific Officer of Olema Oncology. “F...